Loading...
Market
What will be the outcome of FDA's ongoing review of mRNA COVID-19 vaccines by the end of 2024?
2
Resolution / Starting Odds
No change in safety guidelines • 25%
Minor safety warning issued • 25%
Major safety warning issued • 25%
Vaccine approval revoked • 25%
FDA official announcements and press releases
Story
FDA Affirms Safety of mRNA COVID-19 Vaccines Amid Cancer Claims and 600,000 Adverse Events
Sep 6, 2024, 08:42 PM
Recent discussions around the mRNA COVID-19 vaccines have highlighted both their efficacy and safety, as well as concerns about potential adverse effects. Findings from the COVE trial indicate that the mRNA-1273 vaccine is safe and effective against COVID-19, including emergent variants. Dr. Peter Marks from the FDA has affirmed the agency's confidence in the safety and effectiveness of these updated vaccines, noting that they meet rigorous scientific standards. AmeshAA stated, “With the mRNA technology, we're able to produce a vaccine that gives quite potent responses with a very tolerable safety profile.” However, there are claims circulating that Moderna's mRNA vaccines cause cancer and other adverse events. Over 600,000 adverse events have been reported in the United States, including 75,000 ER visits and 36,000 hospitalizations. These claims are juxtaposed with the FDA's assurance of the vaccine's safety profile.
View original story
Similar markets
Support study's findings • 25%
Refute study's findings • 25%
Call for more research • 25%
No official stance • 25%
Full recall • 25%
Partial recall • 25%
No recall but warning issued • 25%
No action • 25%
Safety concerns resolved • 25%
Further investigation required • 25%
Vaccine trials permanently halted • 25%
Other outcome • 25%
Continues to endorse vaccines • 25%
Modifies recommendations • 25%
Withdraws endorsement • 25%
Takes legal action • 25%
No changes recommended • 25%
Some vaccines recommended for elimination • 25%
Enhanced safety protocols recommended • 25%
Comprehensive overhaul of vaccine policies • 25%
Yes • 50%
No • 50%
Continued use without changes • 25%
Usage restrictions for certain age groups • 25%
Temporary suspension • 25%
Permanent ban • 25%
No issues found • 25%
Minor issues found • 25%
Significant issues found • 25%
Undetermined • 25%
Mostly positive • 25%
Mostly negative • 25%
Mixed • 25%
Indifferent • 25%
Confirms higher SAE rate in early batches • 25%
Confirms no difference in SAE rates • 25%
Finds other contributing factors • 25%
Inconclusive results • 25%